Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2024;11(6):1604-1614.
doi: 10.14283/jpad.2024.117.

Multidomain Intervention Trial for Preventing Cognitive Decline among Older Adults with Type 2 Diabetes: J-MIND-Diabetes

Affiliations
Randomized Controlled Trial

Multidomain Intervention Trial for Preventing Cognitive Decline among Older Adults with Type 2 Diabetes: J-MIND-Diabetes

T Sugimoto et al. J Prev Alzheimers Dis. 2024.

Abstract

Background: No multidomain intervention trials have been designed for the prevention of cognitive decline in older adults with type 2 diabetes.

Objectives: To investigate the efficacy of a multidomain intervention in preventing cognitive decline in older adults with type 2 diabetes and cognitive impairment.

Design: Eighteen-month, multi-centered, randomized controlled trial.

Setting: Twelve hospitals in Japan.

Participants: Outpatients with type 2 diabetes aged 70-85 years with cognitive impairment.

Intervention: The multidomain intervention program includes management of metabolic and vascular risk factors, exercise, nutritional counseling, and promotion of social participation. Participants in the control group received usual care and treatment for type 2 diabetes.

Measurements: The primary outcome was the change in a composite score combining several neuropsychological tests from baseline to the 18-month follow-up. To assess the differences in cognitive changes between the intervention and control groups, a mixed-effects model for repeated measures was used.

Results: Between March 13, 2019, and May 8, 2020, 361 participants were screened, and 154 were randomly assigned to either the intervention group (n = 81) or the control group (n = 73). Finally, 110 participants completed the trial. The between-group difference in the composite score changes was 0.068 (95% confidence interval, -0.091 to 0.226). Analyses for secondary outcomes indicated a positive impact of the intervention on memory and indicated that the intervention led to changes in dietary habits with increased intakes of niacin and meat, along with weight reduction compared to the control group.

Conclusion: The multidomain intervention did not demonstrate efficacy in preventing cognitive decline. However, this trial provided proof-of-concept evidence that multidomain interventions may offer cognitive benefits and contribute to changes in dietary behavior and weight reduction in older adults with type 2 diabetes and cognitive impairment. These findings should be confirmed in future studies.

Keywords: Multidomain intervention; cognitive decline; diet; exercise; type 2 diabetes.

PubMed Disclaimer

Conflict of interest statement

TSu declares a research fellowship from the Manpei Suzuki Diabetes Foundation and a grant from the Keiko-Yamasaki Memorial Funds. AA declares honoraria from Novo Nordisk Pharma Ltd, Sumitomo Parma Co. Ltd., and Ono pharmaceutical Co. Ltd. NI declares research grants and contracts from Terumo Co., Drawbridge Inc., Asken Inc., Daiichi-Sankyo Co. Ltd., Mitsubishi Tanabe Pharma Corp., Takeda Pharmaceutical Co. Ltd., Japan Tobacco Inc., Kyowa Kirin Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., MSD K.K., Ono Pharmaceutical Co. Ltd., Nippon Boehringer Ingelheim Co. Ltd., LifeScan Japan K.K., and Kowa Co. Ltd.; honoraria for lectures from Novo Nordisk Pharma Ltd., Nippon Boehringer Ingelheim Co. Ltd., Mitsubishi Tanabe Pharma Corp., Sumitomo Dainippon Pharma Co., Ltd., Sanofi K.K., Eli Lilly Japan K.K., and Kyowa Kirin Co. Ltd. MOg declares honoraria for lectures from AstraZeneca K.K., Ono Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Kowa Co. Ltd., Sanofi K.K., Sumitomo Dainippon Pharma Co. Ltd., Daiichi-Sankyo Co. Ltd., Taisho Pharmaceutical Holdings Co. Ltd., Mitsubishi Tanabe Pharma Corp., Teijin Pharma Ltd., Terumo Co., Eli Lilly Japan K.K., Nippon Boehringer Ingelheim Co. Ltd., Novartis Pharma K.K., and Novo Nordisk Pharma Ltd. Other authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Trial profile MoCA-J, Japanese version of the Montreal Cognitive Assessment
Figure 2
Figure 2
Changes in composite scores (A) and delayed recall test scores of the ROCFT (B) from baseline to the 18-month follow-up *Mean difference in changes in delayed recall test scores of the ROCFT between the intervention and control groups was statistically significant (P < 0.05). ROCFT, Rey-Osterrieth Complex Figure Test
Figure 3
Figure 3
Changes in intakes of nutrients (A) and food groups (B) from baseline to 18-month follow-up The mean changes and the 95% confidence intervals within group were calculated using paired t-tests. The P-value for the mean differences between groups was calculated using the Wilcoxon rank sum test.

References

    1. Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol 2018;14:88–98. 10.1038/nrendo.2017.151 - PubMed
    1. Srikanth V, Sinclair AJ, Hill-Briggs F, Moran C, Biessels GJ. Type 2 diabetes and cognitive dysfunction-towards effective management of both comorbidities. Lancet Diabetes Endocrinol 2020;8:535–545. 10.1016/S2213-8587(20)30118-2 - PubMed
    1. Rawlings AM, Sharrett AR, Albert MS, et al. The association of late-life diabetes status and hyperglycemia with incident mild cognitive impairment and dementia: the ARIC study. Diabetes Care 2019;42:1248–1254. 10.2337/dc19-0120 - PMC - PubMed
    1. Mattishent K, Loke YK. Bi-directional interaction between hypoglycaemia and cognitive impairment in elderly patients treated with glucose-lowering agents: a systematic review and meta-analysis. Diabetes Obes Metab 2016;18:135–141. 10.1111/dom.12587 - PubMed
    1. Rawlings AM, Sharrett AR, Mosley TH, Ballew SH, Deal JA, Selvin E. Glucose peaks and the risk of dementia and 20-year cognitive decline. Diabetes Care 2017;40:879–886. 10.2337/dc16-2203 - PMC - PubMed

Publication types

LinkOut - more resources